CD19 CAR T-Cell Therapy for Autoimmune Hemolytic Anemia

Area of Science:

• Immunotherapy
• Hematology
• Oncology

Background:

• Autoimmune hemolytic anemia (AIHA) presents a high relapse risk due to persistent autoreactive B-cell activity.
• Multirefractory AIHA signifies advanced disease unresponsive to at least three prior therapies.
• CD19-directed chimeric antigen receptor (CAR) T-cell therapy induces B-cell depletion, potentially achieving remission.

Purpose of the Study:

• To evaluate the safety and efficacy of CD19 CAR T-cell therapy in patients with primary multirefractory AIHA.
• To assess adverse events, including cytokine-release syndrome and neurotoxicity.
• To analyze B-cell reconstitution and relapse mechanisms.

Main Methods:

• Eleven patients with multirefractory AIHA received a single infusion of autologous CD19 CAR T cells.
• Safety was assessed via incidence, characteristics, and severity of adverse events.
• Efficacy was determined by complete response rates, duration of remission, and B-cell dynamics using flow cytometry and sequencing.

Main Results:

• All 11 patients achieved a complete response, with a median time to response of 45 days.
• The median duration of drug-free remission was 11.5 months.
• Grade 1-2 cytokine-release syndrome occurred in 9 patients; grade 1 neurotoxicity in 1 patient. Infections and hematotoxicity were generally low-grade.

Conclusions:

• CD19 CAR T-cell therapy demonstrated expected toxicities and achieved sustained remission in multirefractory AIHA.
• The therapy offers a viable option for patients with advanced, treatment-resistant AIHA.
• Further research into B-cell reconstitution and relapse mechanisms is warranted.